Send to

Choose Destination
See comment in PubMed Commons below
Trends Mol Med. 2009 Nov;15(11):491-500. doi: 10.1016/j.molmed.2009.09.001. Epub 2009 Oct 19.

Strategies for targeted nonviral delivery of siRNAs in vivo.

Author information

  • 1Department of Biomedical Sciences, Center of Excellence for Infectious Diseases, Paul L. Foster School of Medicine, Texas Tech University Health Sciences Center, El Paso, TX 79905, USA.


Silencing specific gene expression by RNA interference (RNAi) has rapidly become a standard tool for the reverse genetic analysis of gene functions. It also has tremendous potential for managing diseases for which effective treatment is currently unavailable or suboptimal. However, the poor cellular uptake of synthetic small interfering RNAs (siRNAs) is a major impediment for their clinical use. Great progress has been made in recent years to overcome this barrier, and several methods have been described for the in vivo delivery of siRNA. Moreover, the latest advances have focused on achieving targeted siRNA delivery restricted to relevant tissues and cell types in vivo. These approaches are expected to reduce the dose requirement as well as minimize siRNA-induced toxicities, thereby advancing the field of siRNA therapy towards clinical use.

[PubMed - indexed for MEDLINE]
Free PMC Article
PubMed Commons home

PubMed Commons

How to join PubMed Commons

    Supplemental Content

    Full text links

    Icon for Elsevier Science Icon for PubMed Central
    Loading ...
    Write to the Help Desk